Table 2. Cox regression analysis... | American Society of Hematology

Table 2.

Cox regression analysis

Variable	Univariate			Multivariate (n = 231^†)
Variable	P value	Hazard ratio (95% CI^*)	Wald χ²	P value	Hazard ratio (95% CI^*)	Wald χ²
suPAR	< .0001	1.6	107	< .0001	1.5	33
1 ng/mL higher		(1.5-1.8)			(1.3-1.7)
CD4 count	< .0001	1.6	200	< .0001	1.3	15
50% lower		(1.5-1.7)			(1.1-1.5)
Viral load	< .0001	3.9	94	< .0001	2.0	17
10-fold higher		(3.0-5.2)			(1.4-2.7)
β2-microglobulin	< .0001	3.0	71	.02	1.3	5
2-fold higher		(2.3-3.8)			(1.0-1.6)
Age	.03	1.2	5	.06	1.2	4
10 years older		(1.0-1.4)			(1.0-1.5)
CDC stage B vs A	< .0001	2.7	16	.4	1.3	1
		(1.7-4.4)			(0.7-2.3)
CDC stage C vs A	< .0001	12.3	113	.005	2.8	8
		(7.8-20.0)			(1.4-5.7)
Drug treatment at enrollment	< .0001	2.6	35	.1	1.5	3
(yes vs no)		(1.9-3.7)			(0.9-2.3)

Variable	Univariate			Multivariate (n = 231^†)
Variable	P value	Hazard ratio (95% CI^*)	Wald χ²	P value	Hazard ratio (95% CI^*)	Wald χ²
suPAR	< .0001	1.6	107	< .0001	1.5	33
1 ng/mL higher		(1.5-1.8)			(1.3-1.7)
CD4 count	< .0001	1.6	200	< .0001	1.3	15
50% lower		(1.5-1.7)			(1.1-1.5)
Viral load	< .0001	3.9	94	< .0001	2.0	17
10-fold higher		(3.0-5.2)			(1.4-2.7)
β2-microglobulin	< .0001	3.0	71	.02	1.3	5
2-fold higher		(2.3-3.8)			(1.0-1.6)
Age	.03	1.2	5	.06	1.2	4
10 years older		(1.0-1.4)			(1.0-1.5)
CDC stage B vs A	< .0001	2.7	16	.4	1.3	1
		(1.7-4.4)			(0.7-2.3)
CDC stage C vs A	< .0001	12.3	113	.005	2.8	8
		(7.8-20.0)			(1.4-5.7)
Drug treatment at enrollment	< .0001	2.6	35	.1	1.5	3
(yes vs no)		(1.9-3.7)			(0.9-2.3)

95% CI of the hazard ratio.

Patients for whom data for one or more of the serologic variables was missing (n = 83) were excluded from the analysis (Table 1 shows details).